Repositorio Dspace

Improvement in Antipsychotic-Related Sexual Dysfunction After Switching to Cariprazine: A Prospective Real-World Study

Mostrar el registro sencillo del ítem

dc.contributor.author Montejo, Angel-L
dc.contributor.author Fiorini, Juan-C
dc.contributor.author Megia, Pedro
dc.contributor.author Ochoa, Rubén
dc.contributor.author Arribas, Belén
dc.contributor.author Peraire, Marc
dc.contributor.author Echeverria, Iván
dc.contributor.author Aparicio-Castro, Eladio
dc.contributor.author García-Ullan, Llanyra
dc.date.accessioned 2026-09-17T12:13:34Z
dc.date.available 2026-09-17T12:13:34Z
dc.date.issued 2026-04-27
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28101
dc.description.abstract Background: Sexual dysfunction is a frequent adverse effect of antipsychotic treatment and a major contributor to poor adherence and reduced quality of life. Evidence regarding the impact of switching to prolactin-sparing antipsychotics in routine clinical practice remains limited. This study evaluated changes in sexual function following initiation or switch to cariprazine in real-world patients with schizophrenia spectrum disorders. Methods: In this prospective observational study, adult outpatients were either initiated on cariprazine de novo (Group A) or switched from a previous antipsychotic due to clinically significant sexual dysfunction (Group B). Sexual function was assessed using the Psychotropic-Related Sexual Dysfunction Questionnaire (SALSEX) at baseline and Month 3. Secondary measures included serum prolactin levels and Brief Psychiatric Rating Scale (BPRS) an CGI scores. Effect sizes were calculated using Cohen's d. Results: Forty-two patients were included (Group A: n = 14; Group B: n = 28). In Group B, mean SALSEX total scores significantly decreased from 8.04 ± 2.76 to 2.41 ± 2.06 (? = -5.63; p < 0.001; d = 2.27). Prolactin levels also significantly decreased after switching (p = 0.012). In Group A, SALSEX scores showed a statistically significant but clinically modest reduction (2.79 ± 2.01 to 1.23 ± 1.24; p = 0.023; d = 0.93), with no evidence of treatment-emergent sexual dysfunction. Improvements in sexual function were not associated with changes either in BPRS or CGI scores, baseline symptom severity, sex, or testosterone levels. Conclusions: Switching to cariprazine in patients with antipsychotic-related sexual dysfunction was associated with large and clinically meaningful improvement in sexual function in routine practice. The effect appeared independent of overall symptom improvement and endocrine normalization thresholds, supporting the clinical value of prolactin-sparing switching strategies.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución/Reconocimiento 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.title Improvement in Antipsychotic-Related Sexual Dysfunction After Switching to Cariprazine: A Prospective Real-World Study
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42123053
dc.relation.publisherversion https://www.mdpi.com/2077-0383/15/9/3320
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.3390/jcm15093320
dc.journal.title JOURNAL OF CLINICAL MEDICINE
dc.identifier.essn 2077-0383


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta